Acute myeloid leukemia
Clinically validated testing
We strive to provide the highest quality molecular services available to complement your clinical practice by offering a robust menu of clinically validated testing, including:
- Genetic testing panels, including MayoComplete next-generation sequencing: a comprehensive, 47-gene myeloid neoplasms oncoheme panel and two acute myeloid leukemia (AML)-focused subpanels.
- A comprehensive, disease-specific menu of fluorescence in situ hybridization (FISH) panels.
- Molecular analysis that combines reverse transcription, real-time polymerase chain reaction (RT-PCR) technology, and DNA-based fragment analysis to evaluate measurable residual disease (MRD).
News and updates
The latest
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.
On the brink of losing her battle with acute myeloid leukemia, Shannon Camlek arrived at Mayo Clinic as a last hope. Her chances didn’t look good, but with the help of specialized genetic testing, particularly FISH (fluorescence in situ hybridization) studies, doctors were able to detect the specific gene mutations responsible for her symptoms and disease. The test results also helped Shannon’s care team target her treatment accordingly, and finally put an end to what Shannon likens as starring in her own personal horror movie while in search of hope and healing.
In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.
This algorithm can be viewed here.